CyPath® Lung
Early-stage lung cancer diagnosis
Commercial (LDT)Marketed
Key Facts
Indication
Early-stage lung cancer diagnosis
Phase
Commercial (LDT)
Status
Marketed
Company
About bioAffinity Technologies
bioAffinity Technologies is a public biotech company focused on non-invasive, early-stage cancer diagnostics and targeted treatments. Its core achievement is the commercial launch of CyPath® Lung, a Laboratory Developed Test (LDT) with compelling clinical data (92% sensitivity, 87% specificity for small nodules) that addresses the critical diagnostic gap following indeterminate low-dose CT scans. The company's strategy is to commercialize this first product through its CLIA-certified lab subsidiary while advancing its porphyrin-based platform for broader diagnostic and therapeutic applications in oncology.
View full company profile